A carregar...
TCR diversity – a universal cancer immunotherapy biomarker?
Sipuleucel-T was approved as a treatment for men with advanced metastatic, castration-resistant prostate cancer on the basis of improved survival in randomized clinical trials. A major challenge for this therapy, as well as other newer cancer immunotherapy agents, has been to identify markers that c...
Na minha lista:
| Publicado no: | J Immunother Cancer |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5109785/ https://ncbi.nlm.nih.gov/pubmed/27879971 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-016-0175-4 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|